Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

Stock market today: Dow, S&P 500, Nasdaq pare losses while oil prices jump as Wall Street watches Iran fallout

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq pare losses while oil prices jump as Wall Street watches Iran fallout US stocks began to pare losses through late morning trading on Monday while oil prices surged after military strikes by the US and Israel on Iran were followed by counterattacks, sending shockwaves through glo…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Calling for Iran's leaders to hand power to the nation's people

    80% confidence

  • Iran conflict unlikely to dent bullish market view

    80% confidence

  • Deal expected to close in third quarter with $69 billion in pro-forma revenue, $18 billion in EBITDA, and combined net of $79 billion

    80% confidence

  • Trump has agreed to speak with Iran's new leadership

    80% confidence

  • Oil prices could reach $120 per barrel if war spreads throughout Middle East

    80% confidence

  • Bombing against Iran will continue for several weeks

    80% confidence

  • Computing has fundamentally changed; in the age of AI, software runs on intelligence with tokens generated in real time by AI factories

    80% confidence

  • JPMorgan expects a risk premium gain of up to 10% for gold

    80% confidence

  • Paramount targeting 15 theatrical films a year per studio for total of at least 30 films annually

    80% confidence

  • Company doesn't plan to cut production and WBD purchase is pro-competition, pro-consumer and pro-creative community

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq pare losses while oil prices jump as Wall Street watches Iran fallout — Source | Via News | ViaNews EU